Prevention & lipidsCohort study
One-year treatment trajectories of patients with statin intolerance: results from a multicentre registry
- Prospective registry study
- observational
- multicentre
Authors' conclusion
While LDL-C values improved during follow-up, three in four statin-intolerant patients still did not achieve their LDL-C targets and many patients reported persisting pain, especially women.
Study context
- Population
- Patients with statin intolerance (intolerance to ≥2 different statins), recruited 2021–2023 in Germany1,032 at 1-year follow-up
- Participants
- 1,111 patients
- Outcome
- Treatment trajectories, stratified by persisting pain and patient characteristics
- Follow-up
- one-year follow-up
Main finding
As reported in the abstract
Pain status and treatment course at 1 year
- Persisting pain
- 39.1%
- No pain
- 34.2%
- New pain
- 11.9%
- Resolved pain
- 14.8%
- Lipid-lowering therapy (LLT) escalation
- 43.2%
- LLT de-escalation
- 17.0%
- No change in LLT
- 39.8%
- LDL-C, median (IQR), baseline
- 2.3 (1.6-3.6) mmol/L
- LDL-C, median (IQR), after one year
- 2.0 (1.4-2.8) mmol/L
- LDL-C target attainment, baseline to 1 year
- 18.0 to 24.0%
Observational data: associations, not effects.
Further findings
Characteristics of patients with persisting pain
- More often female, older, more co-morbidities, lower quality of life, more often discontinued LLT
Women vs men
- Women: more often LLT de-escalation and significantly smaller improvement in LDL-C target attainment than men
Original publication
One-year treatment trajectories of patients with statin intolerance: results from a multicentre registry. Eur J Prev Cardiol. Published 27 September 2025. doi:10.1093/eurjpc/zwaf619
Summarised from the published abstract; every number is checked against it